7356-52-7

Basic information

• Product Name: 2-NITRO-3-ACETYLAMINO-4-METHYLBENZOIC ACID
• Synonyms: 2-NITRO-3-ACETYLAMINO-4-METHYLBENZOIC ACID;3-Acetamido-4-methyl-2-nitrobenzoic acid;Benzoic acid, 3-(acetylaMino)-4-Methyl-2-nitro-;3-Acetylamino-4-methyl-2-nitro-benzoic acid
• CAS NO: 7356-52-7
• Molecular Formula: C₁₀H₁₀N₂O₅
• Molecular Weight: 238.2
• Mol File: 7356-52-7.mol

Chemical Properties

• Boiling Point: 489.4°C at 760 mmHg
• Flash Point: 249.8°C
• Appearance: /
• Density: 1.459g/cm³
• Vapor Pressure: 2.15E-10mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-NITRO-3-ACETYLAMINO-4-METHYLBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-NITRO-3-ACETYLAMINO-4-METHYLBENZOIC ACID(7356-52-7)
• EPA Substance Registry System: 2-NITRO-3-ACETYLAMINO-4-METHYLBENZOIC ACID(7356-52-7)

Safety Data

• Hazardous Substances Data: 7356-52-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Nitro-3-acetylamino-4-methylbenzoic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications. Its unique chemical structure allows it to be a key component in the development of new drugs with specific medicinal properties.
Used in Dye Production:
In the chemical industry, 2-Nitro-3-acetylamino-4-methylbenzoic acid is used as a precursor in the production of dyes. Its chemical properties contribute to the color and stability of the dyes, making it a valuable component in this application.
Used in Antibacterial Applications:
2-Nitro-3-acetylamino-4-methylbenzoic acid is studied for its antibacterial properties, making it a potential candidate for use in antimicrobial agents. It can be utilized in the development of new antibiotics or as a component in existing formulations to combat bacterial infections.
Used in Anti-Inflammatory Applications:
Due to its anti-inflammatory effects, 2-Nitro-3-acetylamino-4-methylbenzoic acid is investigated for use in anti-inflammatory medications. It may be incorporated into formulations to help reduce inflammation and alleviate symptoms associated with various inflammatory conditions.
It is important to handle 2-Nitro-3-acetylamino-4-methylbenzoic acid with appropriate caution and under the guidance of a trained professional to ensure safe usage and avoid potential hazards.

InChI:InChI=1/C10H10N2O5/c1-5-3-4-7(10(14)15)9(12(16)17)8(5)11-6(2)13/h3-4H,1-2H3,(H,11,13)(H,14,15)

Upstream product

• 6946-14-1 3-acetylamino-4-methylbenzoic acid 
• 2458-12-0 3-amino-p-toluic acid 

Downstream Products

• 37901-90-9 3-amino-4-methyl-2-nitrobenzoic acid 
• 320740-32-7 3-bromo-4-methyl-2-nitrobenzoic acid 
• 320740-33-8 methyl 3-bromo-4-methyl-2-nitrobenzoate 
• 320740-35-0 2-amino-3-bromo-4-methylbenzoic acid 
• 320740-34-9 methyl 2-amino-3-bromo-4-methylbenzoate 
• 20587-29-5 methyl 4-methyl-2-nitrobenzoate 
• 6946-15-2 3-hydroxy-4-methyl-2-nitro-benzoic acid 

Relevant articles and documents

COVALENT INHIBITORS OF KRAS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a,

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form

6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile, and the anhydrous monoacetate salt thereof, are useful in the treatment of alpha-2 mediated di

The synthesis of C2-symmetric and axially chiral compounds for recognition and catalysis

Axially chiral amidines and guanidines, some possessing C2-symmetry, have been targeted as potential chiral catalysts for reactions of α,β-unsaturated carboxylic acids or esters. The key step in each synthesis required the coupling of two sterically demanding aromatic compounds to form atropisomeric biaryl species. (C) 2000 Elsevier Science Ltd.